Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

ABSTRACT:

Background

The relative risk (RR) of infection for patients treated with immune checkpoint inhibitors (ICIs) is unknown.

Objectives

This study evaluated the risk of infection for patients with solid tumors undergoing ICI therapy based on a systematic review and meta-analysis.

Patients and methods

The Cochrane Library, EMBASE, and Pubmed databases were searched up to 1 December 2020. Randomized trials comparing any ICI alone, with chemotherapy (CT), or with other agents versus placebo, CT, or other agents were included. Three independent reviewers extracted the data. The primary outcome was the RR of all-grade (G) and G3-5 infections for patients receiving ICI-based treatments. Random or fixed-effect models were used according to statistical heterogeneity.

Results</

SUBMITTER: Petrelli F 

PROVIDER: S-EPMC8256230 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature